- It has been tough for ANVS' investors since July 28, when the company presented phase 2a Alzheimer's & Parkinson's results at the Alzheimer's Association International Conference (AAIC).
- The stock had gone from $109.44 on July 28 to $37.10 on Aug 20, a >66% drop, responding to what ANVS claimed to be "positive" p2 data.
- On Aug 11, ANVS put out a Frequently Asked Questions on their website for anyone who wishes to know more details about their p2a trial results.
- I take a close look and share my thoughts.
For further details see:
Annovis Bio: How Positive Is The Data From Their Phase2a Alzheimer's And Parkinson's Trials?